1. Higher brain pain activation predicts better response to TNF inhibitors.
2. 57% of high-activation patients achieved low disease activity at 12 weeks.
3. Functional MRI effectively detects pain-related brain activity.
4. Adverse events varied among groups; no new safety concerns identified.
5. Importance of subjective patient parameters in treatment response highlighted.

Source: The Lancet Rheumatology